UPC APP 34350/2025
EP3854403 Unitary patent · USE OF SUBSTITUTED AMINOPROPIONATE COMPOUNDS IN TREATMENT OF SARS-COV-2 INFECTION
- Case details
- Status—ActionProcedural applicationCategoryOther procedural
- Parties
- Division
- Milan CD
- Judges
- —
- Technology
- ChemistryPharmaceuticals
- Language
- —
- First decided
- Sep 4, 2025
- EPO Opposition
- Gilead Sciences, Inc.Admissible2025-06-18
| Median days to first decision | |
|---|---|
| All UPC | 124 |
| Milan CD | Locked |
At the UPC: Gilead Sciences, Inc. (5 cases)·Academy of Military Medical Sciences (5 cases)
This dispute contains 4 other proceedings
UPC CoA 121/2026·UPC CoA 103/2026·UPC CFI 1968/2026·UPC CFI 552/2025
- 2025-09-04
Summary: Milan Central Division judge-rapporteur issued a procedural order in the revocation action by Gilead Sciences against Academy of Military Medical Sciences (patent EP 3 854 403, Remdesivir for MERS/SARS-CoV-1). The order resolved disputes on the validity of service on the Chinese defendant via its EPO patent representative Lavoix. The court held that service on the patent representative within the CMS was valid under Rule 271(6) RoP. Lavoix's objections to service were inadmissible as the patent representative had no standing to defend the patent holder without a power of attorney. Gilead's premature request for a default judgment was declared currently inadmissible.
Show the legal issues (4)
- Service of proceedings on foreign defendant via EPO patent representative under Rule 271 RoP
- Standing of patent representative to raise procedural objections
- Default judgment admissibility under Rule 355/356 RoP
- Validity of service within vs outside CMS
- EAA9DAF11A1C547DBE32D677B84E5F16_en.pdf2025-09-04EN